CENTER OF MOLECULAR IMMUNOLOGY

Trials shown by sponsor

Public title	Date of Registration	State
Phyisician Led CIMAvax-EGF lung biomarkers	11/03/2021	Registered outdated
Phase II / III. Nimotuzumab in patients with triple-negative breast cancer.	23/05/2014	Registered
Phase I/II trial with the mutein no alfa of IL-2	03/02/2017	Registered outdated
Patients with non small cells lung cancer (NSCLC) and brain metastasis.	2010-12-29	Registered
Nimotuzumab-pancreatic cancer-adults-Phase IV.	30/04/2017	Registered
Nimotuzumab inoperable esophageal epithelial tumors, Phase IV	30/06/2016	Registered
Nimotuzumab in the treatment of patients with acute respiratory difficulty syndrome (ARDS)	03/03/2023	Registered
Nimotuzumab in Non-Small Cell Lung Cancer (NSCLC) of inoperable stage III epidermoid histology, concomitant with Chemo and Radiotherapy (CRT)	28/12/2018	Registered outdated
Nimotuzumab in COVID-19	21/05/2021	Registered
Nimotuzumab cold kit for the immunodiagnosis of solid tumors	05/10/2018	Registered
NGcGM3/VSSP/Montanide ISA 51 vaccine in metastatic breast cancer. Phase II	2010-12-17	Registered
NGcGM3/VSSP/Montanide ISA 51 vaccine for breast cancer IIa, IIb and IIIa surgically treated with positive ganglia and disease-free, Phase IIb/III.	2010-12-17	Registered
NGcGM3/VSSP in small cell lung cancer	07/12/2016	Registered outdated
NGcGM3/VSSP in patients with metastatic hormone-receptor positive and HER2 negative breast cancer	28/11/2016	Registered
NGcGM3/VSSP in Metastatic melanoma	07/12/2016	Registered
NGcGM3/VSSP and nimotuzumab in patients with triple negative breast cancer	12/10/2016	Registered
NeuroEPO-Ataxia-Adults-Phase III	19/11/2020	Registered outdated
NeuroEPO in stroke	02/08/2018	Registered
NeuroEPO in patients with Parkinson disease stage II-III	01/02/2017	Registered
NeuroEPO in patients with Mild-Moderate Alzheimer's disease	01/02/2017	Registered

Registered Trials

Registration process

CENTER OF MOLECULAR IMMUNOLOGY

About the RPCEC

Useful resources